[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Psychothérapique de Nancy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":262},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,72,97,118,146,172,194,211,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100566005","french-validation-of-schizophrenia-proneness-instrument--child-youth-100566005",false,"NCT06649552","French Validation of Schizophrenia Proneness Instrument- Child Youth","SPI-CY-Fr","Inclusion Criteria :\n\n* Patients (men or women) followed at one of the 3 following structures in France : CLIP-Ado Nancy, CH Alpes-Isère, CHRU Lille for a suspected mental state at risk of developing psychosis, as determined by the CAARMS scale and\u002For the SPI-CY scale.\n* Age between 12 and 17 years and 11 months\n* Affiliation with a social security scheme or beneficiary of such a scheme.\n* Native language: French.\n* Adolescents who have been informed of the study, have received the study information note and have not objected to participating in the study\n* At least one of the holders of parental authority having been informed of the study, having received the relevant information note and not having objected to the adolescent participation\n* Consent to audio recording of the SPI-CY scale administration: for the adolescent and at least one parent.\n\nExclusion Criteria:\n\n* Pregnant woman, parturient or nursing mother\n* Person deprived of liberty by judicial or administrative decision\n* Person in a life-threatening emergency\n* Impairment of the subject that makes it difficult, if not impossible, to participate in the trial or to understand the information provided.\n* Abuse or dependence on any substance according to DSM V criteria, excluding cannabis","ALL","12 Years","17 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","The clinical concept of a at risk mental state of developing psychosis is based on the identification of attenuated psychotic symptoms during the prodromal phase of psychoses (Schmidt et al., 2015). Early detection and support of these symptoms can delay the risk of transition to a first psychotic episode (van der Gaag, van den Berg, \\& Ising, 2019).\n\nThe Basic Symptom approach enables detection at the earliest stage of the prodromal phase. It postulates that subtle, subjective manifestations predating attenuated psychotic symptoms are present very early in the prodromal phase of psychosis and also have predictive value for the risk of developing psychosis (F. Schultze-Lutter, 2009). Basic symptoms are assessed using the Schizophrenia Proneness Instrument, available in an adult (SPI-A) and child\u002Fadolescent (SPI-CY) version. These scales are part of the international recommendations for the assessment of patients with a Clinical State at High Risk of Psychosis (CHR-P) (Schmidt et al., 2015; F Schultze-Lutter et al., 2015). The SPI-A is validated in French under the name \"Outil d'Evaluation du Risque Schizophrénique version adulte (OERS-A)\" (Schultze-Lutter et al., 2007. French translation by JR. Teyssier with the collaboration of F. Gamma and P. Loulergue), but no French version of the SPI-CY has yet been validated.\n\nIn collaboration with Dr. Frauke Schultze-Lutter, the investigators have recently published a French translation of the SPI-CY (Schizophrenia Predisposition Instrument - Version for Children and Adolescents, F. Schultze-Lutter, M. Marshall, E. Koch, 2021. French translation by F. Bernardin and C. Dondé). This French translation must now be validated to ensure the inter-rater fidelity of the interview.\n\nWe therefore propose to study the inter-rater reliability of the French version of the SPI-CY by comparing ratings between clinicians who have undergone training in basic symptoms and in administering the SPI-A and SPI-CY tools by Dr. Schultze-Lutter. This validation will be carried out by comparing, on the one hand, the rating of the SPI-CY by a clinician A who has administered it to the patient and, on the other hand, the blind rating of a clinician B on the basis of the interview recorded by clinician A with his patient.\n\nThe investigators will also explore the links between the SPI-CY and other clinical scales such as the Multisensory Hallucination SCale (MHASC) (Demeulemeester et al., 2015), the Prodromal Questionnaire 16 (PQ-16) (Lejuste et al., 2021), the Audiograph (Giersch, Huard, Park, \\& Rosen, 2021) and the Perceptual and Cognitive Aberrations (PCA) (McDonald et al., 2019).",[27],"Clinical High Risk for Psychosis (CHR)",[29,30,31,32,33],"SPI-CY","Basic Symptoms","Psychosis","Clinical High Risk","Ultra High Risk","RECRUITING","2026-04-21",{"date":37,"type":38},"2026-04-24","ACTUAL",{"date":40,"type":38},"2025-02-13",{"date":42,"type":21},"2027-02-01",{"name":44,"class":45},"Centre Psychothérapique de Nancy","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100541484","prevalence-of-dissociative-identity-disorder-in-at-risk-outpatient-groups-reporting-childhood-trauma-100541484","NCT06330467","Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma.","IDENTITY","I - Inclusion Criteria:\n\nI-1: For all groups:\n\n* Male or female\n* Age \\> or = 18\n* Enrolled in or benefiting from a social security scheme\n* Patient fluent in French\n* Patient willing to undergo a psychological evaluation between 1h30 and 3h30\n* Patient with a known history of psychotrauma in childhood before the age of 18 (sexual abuse, mistreatment, school harassment, natural disasters, attacks, etc.).\n* Patient having received and understood complete information on the organization of the research and having given written free and informed consent prior to participation in the study.\n\nI-2 : Patients in the borderline group\n\n* Patients with main diagnosis of emotionally labile personality\n* Patients with at least one psychiatric hospitalization in the last 3 years\n\nI-3 : Patients in the early psychosis group\n\nPatient with a diagnosis of mental state at risk of psychosis according to the criteria defined by CAARMS (Comprehensive Assessment of At Risk Mental State) OR Patients diagnosed with a first psychotic episode on an outpatient basis or following a hospital stay\n\nI-4 : Patients in the functional dissociative crises group\n\nPatients diagnosed with functional dissociative crises by a specialized epileptologist\n\nII- Non-inclusion criteria\n\n* Impairment of the subject making it difficult or not impossible to participate in the trial or to understand the information provided to him\u002Fher\n* Patients with specific difficulties in understanding SCID-D questions\n* Psychiatric condition requiring hospitalization\n* Patients with symptoms of recent toxic consumption (alcohol, cannabis, other ...) disrupting assessment responses\n* Patient taking part in a pharmacological study involving a pro-dissociative molecule of the psychedelic type\n* Pregnant, parturient or nursing mothers\n* Person deprived of liberty by judicial or administrative decision\n* Person in a life-threatening emergency\n* An adult under legal protection (guardianship, curatorship, safeguard of justice)\n* Person unable to give consent and not subject to a legal protection measure","18 Years",{"count":56,"type":21},350,[24],"The investigators will study the prevalence of dissociative identity disorder (DID) in three populations at risk in cases of childhood psychotrauma : patients with a diagnosis of borderline personality, patients with a diagnosis of functional dissociative crises (FDC) and patients with early psychosis.\n\nThe investigators will also study the prevalence of other dissociative disorders and the frequency of complex post-traumatic stress disorder.\n\nThe investigators will also look for correlations between the type of maltreatment in childhood, the age of onset of trauma and the type of diagnosis of dissociative disorders.\n\nThe investigators hope to include 150 borderline patients, 150 FDC patients and 50 early psychosis patients.\n\nData collection will be done via a psychometric administration of 7 self-completion questionnaires as well as the completion of the SCID-D semi-structured interview.",[60],"Dissociative Disorder",[62,31,63,64,65],"Dissociative Identity Disorder (DID)","Functional Dissociative Crises (FDC)","Complex PTSD","Borderline",{"date":37,"type":38},{"date":68,"type":38},"2024-06-04",{"date":70,"type":21},"2026-08-18",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100631381","experience-of-uhr-and-pep-individuals-during-mindfulness-a-qualitative-phenomenological-study-100631381","NCT07499934","Experience of UHR and PEP Individuals During Mindfulness: a Qualitative Phenomenological Study","EMIP","Inclusion Criteria:\n\n* People aged between 15 and 30 years who meet the criteria for UHR or PEP status on the CAARMS scale and have a social functional impact (SOFAS score less than 50 or a decrease of more than 30% in the score)\n\nExclusion Criteria:\n\n* \\- Previous episode of schizophrenia, schizoaffective disorder, or bipolar disorder\n* Previous antipsychotic treatment for more than 12 months\n* Organic mental disorder or intellectual disability\n* Serious suicide\u002Fhomicidal risk (but admissible if this risk has been resolved)\n* Insufficient French language skills\n* Adult unable to give consent and not under legal guardianship\n* Protective measure (guardianship\u002Fconservatorship\u002Fjudicial protection) or under judicial supervision\n* Person deprived of liberty by judicial or administrative decision (including actual involuntary hospitalization)\n* Persons in a life-threatening emergency\n* Not affiliated with a social security scheme\n* Minors without parental authorization\n* Person who refused the audio recording of the interview","15 Years","30 Years",{"count":82,"type":21},20,[24],"The goal of this qualitative study is to explore and describe the lived experiences of individuals at ultra-high risk (UHR) or first episode of psychosis (FEP) who have participated in a group-based mindfulness-based intervention. Secondary objectives include identifying potential adverse effects of a group-based mindfulness-based intervention among UHR or FEP.",[27],[31,87],"mindfulness","2026-03-24",{"date":90,"type":38},"2026-03-30",{"date":92,"type":38},"2026-01-19",{"date":94,"type":21},"2027-07-19",{"name":44,"class":45},2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":80,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":96},"100582975","efficacy-of-mindfulness-in-preventing-progression-to-psychosis-in-individuals-with-an-ultra-high-risk-for-psychosis-100582975","NCT06870305","Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis","EM-PREPS","Inclusion Criteria:\n\n* People aged between 18 and 30 validating the criteria for UHR or PEP status on the CAARMS scale and having a social functional impact (SOFAS score below 50 or a reduction of more than 30% in the score)\n\nExclusion Criteria:\n\n* Previous episode of schizophrenic disorder, schizoaffective disorder or bipolar disorder\n* Previous antipsychotic treatment for more than 12 months\n* Organic mental disorder or intellectual disability\n* Serious suicidal\u002Fhomicidal risk (but admissible if this risk has been resolved)\n* Insufficient French language skills\n* Adult incapable of giving consent and not under legal protection\n* Protection measure (guardianship\u002Fcuratorship\u002Fcourt supervision) or under court supervision\n* Person deprived of liberty by judicial or administrative decision (including forced hospitalisation)\n* Persons in a life-threatening emergency\n* Not affiliated to a social security regime",{"count":105,"type":21},270,[24],"The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment. The secondary objectives were to study the efficacy of a group-based mindfulness intervention: on the reduction of psychotic symptoms; on the maintenance over time (6 months of follow-up) of the efficacy of the intervention on the distress associated with the symptoms of the UHR or PEP state; and on various dimensions associated with care: cognitive functions, anxiety, quality of life.",[27],[31,87],"NOT_YET_RECRUITING",{"date":112,"type":38},"2026-03-25",{"date":114,"type":21},"2029-04",{"date":116,"type":21},"2029-12",{"name":44,"class":45},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100557014","study-of-electrophysiological-markers-of-antidepressants-in-major-depressive-disorder-100557014","NCT06532604","Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder","MESANTIDEP","Inclusion Criteria:\n\n* Diagnosis of a current unipolar depressive episode according to DSM-V criteria\n* Prescription of antidepressant treatment - SSRI or alpha-2 antagonist - by the psychiatrist or referring physician for the current depressive episode\n* Age 18 or more\n* Affiliation with a welfare scheme and native French speakers\n* Complete information on the study received and written informed consent signed\n\nExclusion Criteria:\n\n* Diagnosis of a progressive psychiatric disorder (except MDD and anxiety disorder) according to DSM-V criteria\n* Seasonal character of the depression\n* Current antidepressant treatment\n* Recommended antidepressant treatment other than SSRI or alpha-2 antagonist\n* High suicide risk\n* Retinal or ophtalmologic pathology affecting visual acuity as assessed by the Monoyer scale.\n* History of head trauma, epilepsy or other neurological disorders\n* Participation in another interventional study (including exclusion period)\n* Intellectual disability leading to difficulty participating or impossibility or inability to understand the information provided on the study.\n* Persons cited in Articles L. 1121-5 to L. 1121-8 of the French Public Health Code: pregnant women, parturient or breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under duress, persons admitted to a health or social establishment for other goals than research, minors, adults subject to a legal protection, adults who are unable to express their consent and who are not subject to a legal protection measure.\n* Criteria incompatible with the use of the ERG device: open wound in an area covered or enveloped by the device; implantable medical device (e.g. pacemaker); user at high risk of contagion",{"count":126,"type":21},108,[24],"Major depressive disorder (MDD) is a frequent and particularly disabling disorder. The efficacy of current antidepressants is limited, with 50-60% of patients not achieving a sufficient response to treatment. Indeed, to date, clinicians are unable to predict the therapeutic response a patient will obtain to a given molecule. This often results in several trials of a molecule until clinical efficacy is achieved, with a delay of several months of untreated disease. Achieving faster efficacy by targeting the right molecule for each patient in the 1st line of treatment would limit the morbidity and mortality induced by MDD, and its impact on quality of life. To achieve this goal rapidly, there is a need to identify markers for predicting and monitoring therapeutic response to antidepressants.\n\nThis is why the MESANTIDEP study aims to propose electroretinographic (ERG) biomarkers for predicting therapeutic response at 12 weeks for the two main therapeutic classes of antidepressants prescribed as 1st-line treatment for major depressive disorder: Selective Serotonin Reuptake Inhibitors (SSRIs) and alpha-2 adrenergic receptor antagonists (alpha-2 antagonists). Secondly, investigators will look for ERG biomarkers of therapeutic response at 6 weeks, and 12 weeks, for these two therapeutic classes of antidepressants.\n\nFor this purpose, patients diagnosed with MDD and requiring the initiation of an antidepressant - of the SSRI or alpha-2-antagonist class - will be included. At their inclusion visit, patients will not yet have started their antidepressant treatment and will undergo various tests. These include clinical questionnaires, sleep assessment questionnaires and three ERG tests (fERG, PERG and mfERG). Antidepressant treatment can be started by the patient the day after the inclusion visit. 6 and 12 weeks later, the patient undergoes the same tests as at the inclusion visit to monitor their therapeutic response to the prescribed antidepressant. The identification of electrophysiological markers predictive of therapeutic response to antidepressants is intended to help clinicians in the treatment of MDD patients. More rapid therapeutic intervention tailored to each patient will limit the functional impact, improve quality of life and reduce the morbidity and mortality associated with the disease. These electrophysiological ERG measurements are easy to perform. They are therefore accessible to all, and can be used, through a multimodal approach, in routine clinical practice.",[130],"Major Depressive Disorder",[132,133,134,135,136,137],"Antidepressant","Electroretinography","Precision psychiatry","Selective Serotonin Reuptake Inhibitor","Alpha-2 adrenergic receptor antagonists","Retinal function",{"date":139,"type":38},"2026-03-27",{"date":141,"type":21},"2026-09-01",{"date":143,"type":21},"2028-03-01",{"name":44,"class":45},1,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":16,"minAge":54,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":96},"100543864","sensory-and-cognitive-predictions-and-their-disruptions-in-schizophrenia-100543864","NCT06361407","Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia","SensoSchiz","Inclusion Criteria:\n\n* Male or female;\n* Age between 18 and 60 inclusive;\n* Subject having dated and signed the consent form prior to the start of any trial-related procedure (guardian or curator where applicable);\n* Member of a social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Psychoactive substance use disorders (as defined by the DSM-V) (Diagnostic and Statistical Manual-V);\n* Use of benzodiazepines, hallucinogens (in the period preceding before inclusion, for a duration equivalent to 5 half-lives of the product) or cannabis (in the 2 months preceding inclusion);\n* Neurological pathology or sequelae;\n* Attention deficit hyperactivity disorder (ADHD);\n* Borderline personality disorder;\n* Disabling sensory disorders (visual acuity \\\u003C0.8);\n* Person deprived of liberty or under court protection;\n* Pregnant, parturient or breast-feeding women;\n* Subjects in a period of exclusion defined by another clinical study.",true,"60 Years",{"count":156,"type":21},68,[24],"Disturbances in the sense of self and time could play an important role in the development of psychotic symptoms. Previous work has shown that patients have difficulty preparing to process information on the scale of a second, but are abnormally disturbed by slightly asynchronous information on the millisecond scale. In both cases, the anomalies could explain the patients' unusual experience of time. The hypothesis in neurotypical patients is that small delays or asynchronies asynchronies are treated as irrelevant information and ignored and ignored, whereas in patients suffering from schizophrenia they would disrupt the flow of time. This hypothesis is tested with a new visual illusion.",[160,161],"Schizophrenia","Sensory Processing Disorder",[163,164,165],"sensory prediction","motion perception","prediction error",{"date":112,"type":38},{"date":168,"type":38},"2024-06-28",{"date":170,"type":21},"2027-10-28",{"name":44,"class":45},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":153,"sex":16,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":145},"100518882","study-of-language-disorders-and-interactions-between-mnesic-capabilities-and-semantic-competencies-in-patients-with-psychosis-100518882","NCT06036316","Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis","TDLRipsy","Inclusion Criteria:\n\n* All Groups:\n\n  * Patient affiliated or entitled to a social security scheme\n  * Patient having received informed information on the study and having co-signed, with the investigator, a consent to participate in the study\n  * For minor participants, at least one of the parents or holders of parental authority having been informed of the study, having received the information note relating to it and not having objected to the participation of his or her child\n  * Native language: French\n* ARMS and FEP Patient Group:\n\n  * Age between 16 and 35 years old\n  * Present the criteria for EMRP or FEP as defined by the Comprehensive Assessment of At Risk Mental State (CAARMS) or present the criteria for Disorders of the course of thought to the items of the Schizophrenia Proneness Instrument (SPI-A)\n* Patients with schizophrenia group:\n\n  * Age between 16 and 55 years old\n  * Patient with diagnostic criteria for schizophrenia, as defined by DSM V (American Psychiatric Association, 2015)\n  * Present the criteria for Disorganization of Speech and Formal Thought Disorder as defined by the Thinking, Language and Communication (TLC) Rating Scale.\n* Healthy Volunteers Group:\n\n  * Age between 16 and 55 years old\n  * Parental authorization (of both parents) to participate in the study for minor patients\n\nExclusion Criteria:\n\n* All groups:\n\n  * Pregnant, parturient or nursing mother\n  * Person deprived of liberty by a judicial or administrative decision\n  * Person in a life-threatening emergency\n  * Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * Adult person unable to express their consent and who is not the subject of a legal protection measure\n  * Impairment of the subject making it difficult, if not impossible, for them to participate in the trial or to understand the information given to them\n  * Abuse or dependence of any substance according to DSM V criteria excluding cannabis\n* Healthy Volunteers Group:\n\n  * Evolving psychiatric pathology (axis I of the DSM IV, measured at the MINI) excluding anxiety disorder\n  * Presence of developmental disorder of oral language or written language revealed on clinical examination.","16 Years","55 Years",{"count":182,"type":21},90,[24],"This research concerns the study of language disorders of patients present in the spectrum of psychosis. It is indeed accepted that psychotic disorders are associated with language difficulties, which are only poorly highlighted thanks to reusable tools in clinical practice. These language disorders impact communication, and concern many linguistic domains, thus covering phonology, lexicon, semantics, morphosyntax and pragmatics. It therefore seems relevant to characterize these language disorders and to assess to what extent they interact with the other symptoms of the pathology, in particular the course of the thought disorder and the neuropsychological symptoms. In addition, this study is particularly interested in the interactions between working memory capacities and those related to syntax. It is intended for different patients suffering from psychotic disorders of different intensities, treated in the Psychotherapeutic Center of Nancy. Patients suffering from at-risk mental state (ARMS), first episode of psychosis (FEP) or schizophrenia will benefit from a complete language assessment, evaluating each domain mentioned above, on the expressive and understanding sides. The results of the language assessment will be compared with those of a control group in the same tests. They will also be analyzed with regard to the neuropsychological and psychiatric elements noted in the patient's medical file, in order to highlight possible associations between language skills, neuropsychological and psychiatric symptoms in this patient population.",[31,160,186,187],"At-risk Mental State","Language Disorders",{"date":139,"type":38},{"date":190,"type":38},"2024-01-23",{"date":192,"type":21},"2026-06-01",{"name":44,"class":45},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":153,"sex":16,"minAge":54,"maxAge":154,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":145},"100462058","eeg-and-behavioral-correlates-of-temporal-prediction-in-the-tactile-modality-in-schizophrenia-100462058","NCT05296720","EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia","SchizPredicT","Inclusion Criteria:\n\n* Male or Female;\n* Age between 18 and 60 years inclusive;\n* Subject who has dated and signed the consent form (guardian or custodian prior to the commencement of any trial-related procedures if applicable);\n* Enrolled in a social security plan or beneficiary of such a plan.\n\nExclusion Criteria:\n\n* Psychoactive substance use disorders (as defined by DSM-V);\n* Use of benzodiazepines (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months prior to inclusion; use of cannabis (THC) will be verified with a urine dipstick) or hallucinogenic substances (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product);\n* Neurological pathology or sequelae;\n* Attention deficit hyperactivity disorder (ADHD);\n* A borderline personality disorder;\n* Disabling sensory disorders;\n* Person deprived of liberty or under court protection;\n* Pregnant, parturient or nursing woman;\n* Subject in a period of exclusion as defined by another clinical study.",{"count":156,"type":21},[24],"Patients with schizophrenia have disturbances in their sense of self, particularly their bodily self. Disorders of the sense of self are central to schizophrenia and are of interest because they are thought to be present prior to the development of the disorder, when only a few attenuated symptoms signal a risk of developing psychosis. Finding markers related to the sense of self would make it possible to predict which subjects, among those with minimal psychotic symptoms, will develop psychosis, and thus to better adapt management. Disturbances in the experience of the passage of time that accompany disturbances in the sense of self have been described particularly in subjects at risk of developing psychosis, and would predict the onset of the pathology. However, as with alterations in the sense of self, it can be difficult to get patients to describe their disturbances in the experience of time, and objective measures are required to facilitate detection of these disturbances. In the present protocol an objective measure of temporal perception mechanisms will be tested in relation to the sense of self.\n\nThe tests used in the protocol assess subjects' abilities to benefit from the passage of time and to use these abilities to predict and prepare for the occurrence of an event. The investigators have previously shown that patients with impaired bodily sense of self do not benefit from the passage of time to prepare themselves to process information in the future. The present protocol is aimed at developing a measure more sensitive to the patients' disorders by adding tactile measures.",[160],{"date":112,"type":38},{"date":207,"type":38},"2023-04-13",{"date":209,"type":21},"2027-10",{"name":44,"class":45},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":153,"sex":16,"minAge":54,"maxAge":80,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},"100627279","perception-and-integration-of-sensory-information-in-the-early-stages-of-psychosis-100627279","NCT07446569","Perception and Integration of Sensory Information in the Early Stages of Psychosis","PRIOR-ePSY","Inclusion criteria:\n\nAll groups:\n\n* Age between 18 and 30 years\n* Normal or corrected-to-normal visual acuity\n* Affiliated with or dependent on a social security health insurance plan\n* Provided informed consent and co-signed the study consent form with the investigator\n* Proficient in French\n\nControl group (TEM) specific criteria:\n\n* No current psychiatric disorder (DSM-IV Axis I), except anxiety disorders\n* No lifetime history of (hypo)manic episodes or psychotic disorders\n* No first-degree family history of schizophrenia spectrum disorders\n* No regular use (more than one month continuously) in the past 6 months of the following medications: benzodiazepines, hypnotics, antidepressants, antipsychotics, mood stabilizers, or psychostimulants\n\nClinical High-Risk (CHR) group specific criteria:\n\n-Meet CHR criteria according to CAARMS: Attenuated positive symptoms (APS) below clinical threshold in intensity or frequency OR Brief Limited Intermittent Psychotic Symptoms (SPLI) OR Genetic Risk\n\nFirst-Episode Psychosis (PEP) group specific criteria:\n\n-Meet PEP criteria according to CAARMS (psychosis threshold reached)\n\nExclusion criteria:\n\n* Pregnant, postpartum, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals in a life-threatening emergency\n* Adults under legal protection measures\n* Adults unable to provide consent and not under legal protection\n* Impairment that makes participation in the study or understanding of information difficult or impossible\n* Alcohol dependence (AUDIT score ≥12 for men, ≥11 for women)\n* Current substance use disorder (DAST score \\>6)\n* Cannabis use disorder (CUDIT-R score ≥13)\n* History of neurological disorders, including progressive neurological disease\n* Progressive retinal disease\n* Chronic glaucoma\n* Ophthalmologic conditions affecting visual acuity\n* Current eye infection\n* Hearing disorders affecting auditory acuity\n\nCriteria incompatible with the electroretinographic device:\n\n* Presence of photosensitive epilepsy\n* Allergy to components of the electrode gel\n* Behavioral problems causing extreme agitation or aggression\n* Eye or surrounding tissue lesions that may come into contact with the device",{"count":219,"type":21},294,[24],"The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls. The main questions it aims to answer are:\n\n* Can anomalies in visual and auditory sensory processing serve as early markers of psychosis risk?\n* How are these sensory anomalies related to clinical symptom severity and emotional recognition deficits?\n\nResearchers will compare CHR and PEP participants to healthy controls to see if sensory processing differences can help identify individuals at higher risk of developing psychosis.\n\nParticipants will:\n\n* Complete behavioral tasks evaluating visual processing (contrast sensitivity, contour integration, facial emotion recognition, visual inference using Necker cubes) and auditory processing (tone-matching, auditory emotion recognition). A temporal perception component will also be assessed within the auditory and emotion recognition tasks, rather than as a separate task.\n* Undergo electrophysiological assessments of retinal function using flash stimulation to record retinal potentials (a-wave, b-wave, phNR, oscillatory potentials).\n* Provide demographic, clinical, and neuropsychological data during study visits.\n* For CHR participants, attend follow-up visits up to 6 months post initial assessments to evaluate psychotic symptom progression.",[223,224],"Early Psychosis","Schizophrenia Prodromal","2026-02-26",{"date":227,"type":38},"2026-03-03",{"date":229,"type":21},"2026-04",{"date":231,"type":21},"2028-11",{"name":44,"class":45},4,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":145},"100488189","creation-and-evaluation-of-a-mobile-intervention-team-in-perinatal-psychiatry-0-3-years-in-meurthe-et-moselle-sud-100488189","NCT05636878","Creation and Evaluation of a Mobile Intervention Team in Perinatal Psychiatry (0-3 Years) in Meurthe-et-Moselle Sud","EMPER","Inclusion Criteria:\n\n* Children benefiting from EMPPer intervention\n* Children affiliated or entitled to a social security system\n* Children for whom the holder of parental authority has received informed information about the study and has co-signed, with the investigator, a consent to participate in the study\n\nExclusion Criteria:\n\n* Children whose parents are visiting the region ( vacations, family visits ...)\n* Children for whom the 2 holders of parental authority do not speak french\n* Children for whom both parents do not know how to read","1 Day","3 Years",{"count":244,"type":21},4260,[24],"The research system is a Mobile Perinatal Psychiatry Team (EMPPer), for children aged 0 to 3 and their parents. it facilitates access to psychiatric care by going to families who need it and who are in difficulty to ensure this process.\n\nThis device, already deployed in a dozen French cities for several years, convinced the teams of its interest, without demonstrating its effectiveness by evaluation conducted according to research standards. The deployment of a Mobile Perinatal Psychiatry Team in a region not yet equipped (Meurthe-et-Moselle Sud) would therefore offer the opportunity to assess its effectiveness,\n\nThe main objective of the research is to evaluate the effect of the EMPPer on the prevalence of abnormalities in the psychomotor development of children at the age of 2 years, in comparison with similar territories that do not benefit from it, and in comparison with the period preceding the establishment of the EMPPer in the targeted territory.",[248],"Abnormality",[250,251,252,253],"Perinatal","Psychiatry","psychomoteur","children","2024-02-07",{"date":256,"type":38},"2024-02-08",{"date":258,"type":38},"2023-08-18",{"date":260,"type":21},"2028-08-18",{"name":44,"class":45},""]